Icon Writers
RTsafe, a leading medical technology company specialising in quality assurance (QA) solutions for radiation therapy, and Icon Group (Icon), today announced the purchase of two RTsafe PRIME phantoms.
Used together with RTsafe’s independent remote dosimetry services, it enables a comprehensive verification of complex stereotactic and other high-precision radiotherapy treatments, assessing the entire treatment chain from imaging and planning through patient setup and dose delivery. The RTsafe PRIME phantom and the related RTsafe dosimetry services, is also the exclusive phantom used by the International Stereotactic Radiosurgery Society (ISRS) in its ISRS Certification Service, providing centres with a recognised, standardised pathway to demonstrate the accuracy and robustness of their radiosurgery programs.
Icon has acquired the PRIME phantoms to support its existing quality assurance programs for stereotactic radiosurgery across its Icon Cancer Centre locations in Australia. Each PRIME phantom will be deployed across the network, enabling local teams to rigorously verify complex treatment plans as they introduce and expand advanced stereotactic radiosurgery programs across their fleet of Varian linacs (TrueBeam, Halcyon and Ethos), Elekta’s Leksell Gamma Knife and Accuray’s CyberKnife. By partnering with RTsafe, Icon strengthens its ability to provide clinicians with the confidence to deliver advanced treatment techniques safely and effectively translating into greater reassurance for patients and their families.
“Our collaboration with Icon reflects a shared ambition to continually elevate the standards of cancer care,” said Evangelos Pappas, Founder and CSO of RTsafe. “At RTsafe, our goal is to bring certainty to radiotherapy—giving clinicians robust, independent evidence that complex treatments are delivered as intended, and giving patients peace of mind that their safety is carefully safeguarded at every step.”
“At Icon we have a strong track-record and commitment to investing in the latest cutting-edge treatments and technologies to improve the way we deliver care,” said Trent Aland, Icon Group’s Executive Manager – Clinical Care. “The introduction of these phantoms will further enhance our quality assurance and enable the safe delivery of complex and highly advanced treatments for the benefit of teams and our patients.”
Looking ahead, the collaboration is expected to open new avenues for clinical and research initiatives across Icon Group’s network in Australia and its broader footprint in Asia-Pacific and the UK, highlighting the role of international partnerships in advancing global standards of cancer care.